RT @EQRxINC: New pivotal Phase 3 data at #ESMO21: our anti-PD-L1 antibody demonstrated a PFS benefit in Stage III #NSCLC patients after tre…
RT @EQRxINC: New pivotal Phase 3 data at #ESMO21: our anti-PD-L1 antibody demonstrated a PFS benefit in Stage III #NSCLC patients after tre…
© Nextech Invest Ltd. | privacy policy